A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Abstract
ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castration-resistant prostate cancer (mCRPC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1707
Entities
People
- Allan J. Pantuck
- David M. Nanus
- Elisabeth I Heath
- Eric Campeau
- Eric J Small
- Felix Y. Feng
- Joshi J Alumkal
- Karen Norek
- Lisa Bauman
- Margo Snyder
- Michael T Schweizer
- Rahul Aggarwal
- Sanjay Lakhotia
- Sarah Attwell
- Wassim Abida
Organizations
- Fred Hutchinson Cancer Center
- Prostate Cancer Foundation
- Prostate Cancer Foundation of Australia
- United States Department of Defense
- University of Michigan
- Wayne State University